CliffBio
small molecule

ZIMHI

NALOXONE HYDROCHLORIDE

Loss of exclusivityJune 2041latest FDA-listed patent expiry
CompanyZMI →See this company's full patent-cliff portfolio

Drug detail

Brand nameZIMHI
Active ingredientNALOXONE HYDROCHLORIDE
Strength5MG/0.5ML (5MG/0.5ML)
Dosage formSOLUTION
RouteINTRAMUSCULAR, SUBCUTANEOUS
ModalitySmall molecule
FDA approvalOctober 2021
Marketing statusRX

Listed patents

PatentExpiresType
11571518June 2041product
11027072May 2039product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.